IC4: a new combined predictive index of mortality in idiopathic pulmonary fibrosis.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 27 1 2021
medline: 14 7 2022
entrez: 26 1 2021
Statut: ppublish

Résumé

While a number of individual patient characteristics are associated with survival in idiopathic pulmonary fibrosis (IPF), their incorporation into combined indexes, such as the GAP index, has been shown to increase the predictive capacity. It is unknown whether the predictive capacity of GAP-derived indexes that also include anthropometric and exercise parameters is superior to the original instrument. We tested the four-year survival predictive capacity of a modified, adimensional and multiplicative GAP index (IC4) that included percent forced vital capacity (FVC%), diffusing capacity of the lung for carbon monoxide (DLCO%), Body Mass Index (BMI), and six-minute walk distance (6MWD) in 90 IPF patients recruited from two centers in France and Italy. In ROC comparisons, the AUC of the IC4 (0.859, 95% CI 0.770-0.924 P<0.0001) was significantly higher than the AUCs of the individual components, their two-three component combinations, and the original GAP index, with 77% sensitivity and 89% specificity. Mean survival was 14.0±11.7, 23.2±12.7, 34.9±14.8, and 40.8±12.9 months, and survival rate was 0%, 14%, 39% and 73%, in IC4 quartile 1, 2, 3, and 4, respectively. The IC4, a combined non-dimensional index incorporating FVC%, DLCO%, BMI and 6MWD, provides superior capacity to predict mortality, when compared to its individual components, their other combinations, and the GAP index, in patients with IPF.

Sections du résumé

BACKGROUND BACKGROUND
While a number of individual patient characteristics are associated with survival in idiopathic pulmonary fibrosis (IPF), their incorporation into combined indexes, such as the GAP index, has been shown to increase the predictive capacity. It is unknown whether the predictive capacity of GAP-derived indexes that also include anthropometric and exercise parameters is superior to the original instrument.
METHODS METHODS
We tested the four-year survival predictive capacity of a modified, adimensional and multiplicative GAP index (IC4) that included percent forced vital capacity (FVC%), diffusing capacity of the lung for carbon monoxide (DLCO%), Body Mass Index (BMI), and six-minute walk distance (6MWD) in 90 IPF patients recruited from two centers in France and Italy.
RESULTS RESULTS
In ROC comparisons, the AUC of the IC4 (0.859, 95% CI 0.770-0.924 P<0.0001) was significantly higher than the AUCs of the individual components, their two-three component combinations, and the original GAP index, with 77% sensitivity and 89% specificity. Mean survival was 14.0±11.7, 23.2±12.7, 34.9±14.8, and 40.8±12.9 months, and survival rate was 0%, 14%, 39% and 73%, in IC4 quartile 1, 2, 3, and 4, respectively.
CONCLUSIONS CONCLUSIONS
The IC4, a combined non-dimensional index incorporating FVC%, DLCO%, BMI and 6MWD, provides superior capacity to predict mortality, when compared to its individual components, their other combinations, and the GAP index, in patients with IPF.

Identifiants

pubmed: 33496152
pii: S0031-0808.21.04144-6
doi: 10.23736/S0031-0808.21.04144-6
doi:

Substances chimiques

Carbon Monoxide 7U1EE4V452

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

228-234

Auteurs

Angelo Zinellu (A)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy - azinellu@uniss.it.

Claudia Collu (C)

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari Italy.

Elisabetta Zinellu (E)

Unit of Respiratory Diseases, Sassari University Hospital, Sassari, Italy.

Kaïs Ahmad (K)

Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.

Mouhamad Nasser (M)

Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.

Julie Traclet (J)

Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.

Elisabetta Sotgiu (E)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Sabrina Mellino (S)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Arduino A Mangoni (AA)

Department of Clinical Pharmacology, College of Medicine and Public Health, Flinders University and Flinders Medical Center, Adelaide, Australia.

Ciriaco Carru (C)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Pietro Pirina (P)

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari Italy.
Unit of Respiratory Diseases, Sassari University Hospital, Sassari, Italy.

Vincent Cottin (V)

Department of Respiratory Medicine, National Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Lyon, France.
UMR754, Claude Bernard University Lyon 1, Lyon, France.

Alessandro G Fois (AG)

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari Italy.
Unit of Respiratory Diseases, Sassari University Hospital, Sassari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH